chloroquine has been researched along with epoxomicin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avery, VM; Sykes, ML | 1 |
| Albuquerque, IS; Burojević, J; D'Alessandro, S; Djurković-Djaković, O; Konstantinović, J; Machado, M; Pecic, S; Prudêncio, M; Sciotti, RJ; Šolaja, BA; Srbljanović, J; Štajner, T; Taramelli, D; Terzić, N; Tot, M; Verbić, T; Zlatović, M | 1 |
| Alfano, G; Brindisi, M; Brogi, S; Butini, S; Caldelari, R; Campiani, G; Chemi, G; D'Alessandro, S; Dechering, KJ; Fusi, F; Gemma, S; Gorelli, B; Jez, JM; Koolen, KJM; Lamponi, S; Lee, SG; Parapini, S; Saponara, S; Taramelli, D; Vallone, A | 1 |
| Andrews, KT; Antonova-Koch, Y; Avery, VM; Diedrich, D; Duffy, S; Fisher, G; Gebru, T; Hansen, FK; Held, J; Hesping, E; Kurz, T; Meister, S; Schöler, A; Stenzel, K; Winzeler, EA | 1 |
| Closs, EI; Förstermann, U; Habermeier, A; Jaenecke, I; Karbach, S; Martiné, U; Simon, A; Slenzka, A | 1 |
| Aminake, MN; Brouwer, AJ; Joanny, F; Jonker, AM; Knittel, S; Liskamp, RM; Mordmüller, B; Pradel, G; Tschan, S; Wagner, L; Werkhoven, PR | 1 |
| Becker, HJ; Kondo, E; Shimabukuro-Vornhagen, A; Theurich, S; von Bergwelt-Baildon, MS | 1 |
1 review(s) available for chloroquine and epoxomicin
| Article | Year |
|---|---|
Approaches to protozoan drug discovery: phenotypic screening.
Topics: Drug Discovery; Humans; Molecular Structure; Neglected Diseases; Phenotype; Plasmodium falciparum; Protozoan Infections; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma cruzi | 2013 |
6 other study(ies) available for chloroquine and epoxomicin
| Article | Year |
|---|---|
Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
Topics: Aminoquinolines; Animals; Antimalarials; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; Hemin; Hepatocytes; Humans; In Vitro Techniques; Liver; Mice; Microsomes, Liver; Parasite Load; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship; Tetraoxanes | 2016 |
Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analog
Topics: Antimalarials; Dose-Response Relationship, Drug; Enzyme Inhibitors; Furans; Life Cycle Stages; Malaria, Falciparum; Methyltransferases; Molecular Structure; Parasitic Sensitivity Tests; Piperidines; Plasmodium falciparum; Structure-Activity Relationship | 2018 |
One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
Topics: Acetylation; Antimalarials; Hep G2 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Malaria, Falciparum; Peptoids; Plasmodium falciparum; Protozoan Proteins | 2018 |
Relative contribution of different l-arginine sources to the substrate supply of endothelial nitric oxide synthase.
Topics: Arginine; Atherosclerosis; Biological Transport; Cell Line; Chloroquine; Chromatography, High Pressure Liquid; Citrulline; Dipeptides; Endothelium, Vascular; Genes, Reporter; Histidine; Human Umbilical Vein Endothelial Cells; Humans; Leupeptins; Lysosomes; Membrane Transport Proteins; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteolysis | 2011 |
Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors.
Topics: Animals; Antimalarials; Chloroquine; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Female; HEK293 Cells; HeLa Cells; Humans; Leupeptins; Mice; Oligopeptides; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Schizonts; Sulfinic Acids | 2013 |
Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.
Topics: Antigen Presentation; B-Lymphocytes; CD40 Antigens; Chloroquine; Cytosol; Dendritic Cells; Epitopes; Histocompatibility Antigens Class II; Humans; Lymphocyte Activation; Oligopeptides; Proteasome Endopeptidase Complex; Signal Transduction; T-Lymphocyte Subsets | 2016 |